Guggenheim analyst Seamus Fernandez said the total addressable market for GLP-1 drugs like Ozempic and Wegovy could balloon to $150 billion to $200 billion.
Needham raised the price target for Extreme Networks, Inc. (NASDAQ: EXTR) from $30 to $35. Needham analyst Alex Henderson maintained a Buy rating. Extreme Networks shares fell 1.7% to $29.70 in pre-market trading.